Despite the success of COVID-19 vaccines and the implementation of nonpharmaceutical public health measures, there is an enormous global need for effective therapeutics for SARS-CoV-2 infection. At present, repurposed anti-inflammatory drugs (dexamethasone, tocilizumab, and sarilumab),
1-3 monoclonal antibodies,
4-6 and antivirals (remdesivir, molnupiravir, and nirmatrelvir/ritonavir)
7-9 have demonstrated treatment benefits at different stages of COVID-19.
10